anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The skin is the primary feeding site of ticks that infest livestock animals such as cattle. The highly specialised functions of skin at the molecular level may be a factor contributing to variation in susceptibility to tick infestation; but these remain to be well defined. The aim of this study was to investigate the bovine skin transcriptomic profiles of tick-naïve and tick-infested cattle and to uncover the gene expression networks that influence contrasting phenotypes of host resistance to ticks. RNA-Seq data was obtained from skin of Brangus cattle with high (n = 5) and low (n = 6) host resistance at 0 and 12 weeks following artificial tick challenge with Rhipicephalus australis larvae. No differentially expressed genes were detected pre-infestation between high and low resistance groups, but at 12-weeks there were 229 differentially expressed genes (DEGs; FDR < 0.05), of which 212 were the target of at least 1866 transcription factors (TFs) expressed in skin. Regulatory impact factor (RIF) analysis identified 158 significant TFs (P < 0.05) of which GRHL3, and DTX1 were also DEGs in the experiment. Gene term enrichment showed the significant TFs and DEGs were enriched in processes related to immune response and biological pathways related to host response to infectious diseases. Interferon Type 1-stimulated genes, including MX2, ISG15, MX1, OAS2 were upregulated in low host resistance steers after repeated tick challenge, suggesting dysregulated wound healing and chronic inflammatory skin processes contributing to host susceptibility to ticks. The present study provides an assessment of the bovine skin transcriptome before and after repeated tick challenge and shows that the up-regulation of pro-inflammatory genes is a prominent feature in the skin of tick-susceptible animals. In addition, the identification of transcription factors with high regulatory impact provides insights into the potentially meaningful gene-gene interactions involved in the variation of phenotypes of bovine host resistance to ticks.
1,261,454. Analgesic compositions. ELI LILLY & CO. 4 March, 1969 [4 March, 1968], No. 11544/69. Heading A5B. An analgesic composition comprises (i) a first substance in an amount which in the presence of the second substance is analgesically effective, the first substance being α-dpropoxyphene or a pharmaceutically acceptable salt thereof, and (2) a second substance in an amount which potentiates the first substance, the second substance being (a) chlordiazepoxide or a pharmaceutically acceptable salt thereof and/or (b) diazepam or a pharmaceutically acceptable salt thereof. Other active ingredients such as acetylsalicylic acid, acetophenetidine, acetaminophen and codeine may also be present. The composition may be in the form of a two-component pack.
A parasiticidal formulation is provided. This formulation includes a pyrrolidone solvent, a bridging solvent, and an parasiticidal agent. One or more parasiticidal agents may be included in the formulation. Preferably, the formulation contains both closantel and ivermectin. Another aspect of the present invention is a method of making this parasiticidal formulation. This method includes mixing a pyrrolidone solvent and a bridging solvent to form a solvent solution and adding one or more parasiticidal agents to the solvent solution. A further aspect of the present invention is a method for administering the parasiticidal formulation of the present invention to an animal. This method of administration includes providing the parasiticidal formulation described above and applying this formulation to the skin of an animal, wherein the formulation is absorbed through the animal's skin.
Mineral oils are solidified or gelatinized by such proportions of soap and natural or artificial beeswax or essential constituents - cerotic acid and/or alcohol - of such wax that the product contains 1--5 per cent of beeswax and 2--8 per cent of soap.  Alcohol or other solvent may be mixed with the soap, and paraffin, ceresine, or other wax with the beeswax.  To the products may be added scents or cosmetic or therapeutic substances, e.g. formaldehyde, paraformaldehyde, oil of eucalyptus, lemon, rosemary, thyme, mirbane, or camomile.  The jelly-like products may be rendered pulverulent by adding magnesium carbonate, talcum, or other suitable solid or solids. The products may be used as lubricants or cosmetics, for treating chilblains, for surgical treatment, for destroying lice, mosquitos, &c., and for promoting the growth of hair.  In an example, 1000 gm. of petroleum or a fraction of brown-coal tar and a mixture of 30 gm. of medicated soap with 50 gm. of methylated spirit are stirred or sprayed into 50 gm. of melted beeswax at 30 DEG C.ALSO:Mineral oils are solidified or gelatinized by such proportions of soap and natural or artificial beeswax or essential constituents-cerotic acid and/or alcohol-of such wax that the product contains 1-5 per cent of beeswax and 2-8 per cent of soap.  Alcohol or other solvent may be mixed with the soap, and paraffin, ceresine, or other wax with the beeswax.  To the products may be added scents or cosmetic or therapeutic substances, e.g. formaldehyde, paraformaldehyde, oil of eucalyptus, lemon, rosemary, thyme, mirbane, camomile, or two or more.  The jelly-like products may be rendered pulverulent by adding magnesium carbonate, talcum, or other suitable solid or solids.  The products may be used as lubricants or cosmetics, for treating chilblains, for surgical treatment, for destroying lice, mosquitos, and other insects and parasites, and for promoting the growth of hair.  In an example, 1000 gm. of petroleum or a fraction of brown-coal tar and a mixture of 30 gm. of medicated soap with 50 gm. of methylated spirit are stirred or sprayed into 50 gm. of melted beeswax at 30 DEG  C.
PROBLEM TO BE SOLVED: To improve a deodorization property and antibacterial property by forming a deodorant from an effective component represented by a specified formula of a 7,14-diethyl-3,10-disubstituted benzodipteridine. SOLUTION: This deodorant is formed from an effective component of a 7,14-diethyl-3,10-disubstituted benzodipteridine represented by the formula. R1, R2 in the formula are each hydrogen, vinyl, an alkoxycarbonyl, carboxy, and cyano, and are the same as of different from each other. Letters m, n, are integral numbers from zero to six, and are the same as or different from each other. For example, R1 and R2 may preferably be hydrogen atoms of 7,14- diethyl-3,10-dihydrobenzodipteridine. Deodorization efficiency and antibacterial efficiency of the deodorant are improved by deodorization efficiency and antibacterial efficiency of the 7,14-diethyl-3,10-dimethylbenzodipteridine.
Traumatic brain injury (TBI) is a condition affecting the persons' central nervous system with a need for extensive and highly specialized initial health care provision followed by comprehensive rehabilitation efforts. Frequent and life-long medical, cognitive, emotional and behavioral changes are expected. The community-based services are largely responsible for dealing with the chronic challenges affecting people with TBI.

120 patients \>16 years at the time of injury and between 18 and 72 years at inclusion, with clinical TBI diagnosis on acute admission and verified injury-related intracranial abnormalities reporting cognitive, emotional and physical problems more than 2 years after the injury will be included and randomized to a patient-centered in-home program intervention and treatment as usual. The intervention consists of individualized and goal-oriented strategies provided in the persons' home environment in close collaboration with family members and local health care providers. The original protocol describes a total of 8 sessions of which 2 will be telephone based. Due to the Corona pandemic hittting Norway in March 2020 the home visits had to be reduced and adapted to the individual situation of the participants. The protocol now includes 8 sessions with up to 6 of them being delivered by video. The intervention will be provided in addition to the usual treatment the participants receive in the municipality. The control group will receive the usual treatment provided in the municipality. Assessments will be conducted at baseline, at the end of the intervention 4-5 months after inclusion and one year after inclusion. Primary outcome is participation (Part-O) and TBI specific health related quality of life (Qolibri). Secondary outcomes include goal attainment within individualized targeted outcome areas, depression and anxiety, symptom burden, unmet health care needs and acceptability of intervention as assessed by patient, family member and health professional. In March 2020 a few additional questions regarding the impact of the Corona pandemic on health and participation has been included. The closedown periods of the Norwegian Society during Covid-19 will be used as covariate and/or predictors in the analysis. The project will contribute to increased understanding of knowledge transfer processes, and dissemination of evidence based practice for TBI. Thus, the project has the potential to improve the current health care for patients with TBI and its delivery.
BACKGROUND: Myocardial work (MW) is a new echocardiographic tool with a high sensitivity to detect early and subtle alterations of myocardial function. We aimed to evaluate the late effects of anthracyclines by assessing the global and segmental MW and intraventricular mechanical dispersion from speckle tracking echocardiography in childhood lymphoma survivors (CLS).
METHODS: Thirty-one young adults including CLS and age-matched healthy controls were enrolled. All underwent echocardiography including an evaluation of left ventricular (LV) morphology and regional function. We assessed LV longitudinal (differentiating sub-endocardial and sub-epicardial layers), circumferential strains and twist, global and regional MW index (MWI). LV mechanical dispersion was assessed from the time dispersion of LV longitudinal strain, from myocardial wasted work (MWW) and myocardial work efficiency (MWE).
RESULTS: The longitudinal strains both at the level of the sub-endocardium and sub-epicardium were reduced in CLS compared to controls. The global MWI was also decreased (1668 ± 266 vs 1870 ± 264%.mmHg in CLS patients and controls, respectively, p < 0.05), especially on the apical segments. An increase of LV intraventricular mechanical dispersion was observed in CLS. MWW and MWE remained unchanged compared to controls.
CONCLUSION: Our results strongly support that cardiac remodeling is observed in CLS, characterized by a decrease in MW and an increase in LV mechanical dispersion. The apex is specifically altered, but its clinical significance remains uncertain. MW as a complement to strain seems interesting in cancer survivors to detect myocardial dysfunction at early stage and adapt their follow-up.
The invention relates to a method for controlling an injection device (5), which method ensures error-free operation. The patient data (D) of the patient (2) to be treated is determined and the injection agent (K) applied in the injection device (5) is automatically identified according to a first method variant in that the injection device (5) automatically reads out a marking (32) applied to a container (21) of the injection agent (K). Furthermore, contraindications (G) for the identified injections (K) are determined. Comparing the patient data (D) with the or each determined contraindication (G), wherein if at least one contraindication (G) coincides with the patient data (D), at least one protective measure for preventing an injection is taken. According to a second method variant, patient data (D) of the patient (2) to be treated and contraindications (G) for the selected injection (K) are determined. Comparing the patient data (D) with the or each determined contraindication (G), wherein at least one injection (K) is recommended whose contraindication (G) does not correspond to the patient data (D).
Inhibition of neovascularization is achieved by exposing a tissue susceptible to neovascularization to a therapeutic agent effective to inhibit ADAM 9 and/or ADAM 15. The therapeutic agent may be, for example, an antibody, a small molecule therapeutic, an antisense or RNAi therapeutic, or an agent for introducing targeted mutations in the genetic sequence for ADAM9 and/or ADAM 15. Thus, an individual suffering from a condition associated with pathological neovascularization is treated by administration of a therapeutic agent effective to inhibit a ADAM 9 or ADAM 15. Activation of ADAM9 or ADAM 15 can be used for promotion of neovascularization, for example to facilitate wound healing, perfusion or circulation. In this case, the therapeutic agent used is one which enhances the active amount of ADAM9 and/or ADAM15. Inhibition or activation of ADAM9 and/or ADAM15 in accordance with the methods of the invention provides an attractive alternative to targeting of other ADAM species, such as ADAM10, because neither ADAM9 nor ADAM15 appears to be essential for development or maintenance. Thus, side effects are minimised.
Postpartum depression (PPD) seriously impairs the physical and mental health of mothers and their offspring, so how to prevent the occurrence of PPD has essential significance. Esketamine is a common general anesthetic that produces rapid and sustained antidepressant effects. However, the efficacy and safety of perioperative esketamine administration for PPD prevention remain uncertain. We conducted a meta-analysis to determine the effect of perioperative intravenous esketamine on PPD. Randomized controlled trials were included. The primary outcome was the prevalence of PPD and postpartum Edinburgh Postnatal Depression Scale (EPDS) scores. Secondary outcomes included postoperative pain scores and esketamine-related adverse effects. Seven studies included 669 patients treated with esketamine and 619 comparisons. Esketamine could effectively reduce EPDS scores and the incidence of PPD after cesarean section. Even at 42 days postpartum, the incidence of PPD was still significantly lower in the esketamine group. Esketamine did not increase the incidence of postoperative nausea and vomiting, dizziness, and drowsiness. In the esketamine low-dose subgroup, postoperative nausea and vomiting were significantly lower in the esketamine group. The two groups had no significant difference in postoperative pain scores. In conclusion, using esketamine during the perioperative period can reduce the incidence of PPD without increasing adverse effects.
A patient analyte information display system is disclosed. Embodiments of the invention provide for real time, persistent graphical monitoring of a patient analyte, in a historical context. A monitoring system stores and displays numerical values over time for an analyte such as blood glucose, where each value is determined based on sensor input. In some embodiments, these values can be compared to a stored limit or stored limits, which may define an acceptable range for the analyte. A graphical attribute of the display device can be set in accordance with how the numerical values compare to a the set limits in order to notify caregivers when the analyte level deviates from the acceptable range. The capability to statistically analyze analyte values over time can also be provided to enhance the display and/or project future analyte levels.
The study is a prospective, randomized study to compare two common techniques of urethroplasty used to treat bulbar urethral strictures. One technique is excision of the stricture and end-to-end anastomosis of the urethra. The other technique is an onlay grafting procedure with buccal mucosa where the corpus spongiosum is not divided. The study is designed to compare complications of sexual and penile function, and is not powered to compare the success rates of the two techniques. The primary endpoint will be degree of erectile dysfunction and penile complications. The secondary endpoint will be restricturing leading to reoperation, and other complications.
Several studies have reported an unwanted adverse effect of weekend admission on mortality in certain acute medical conditions. Though the reason for this variation could be illness severity, some studies have hypothesized that this could be due to variation in care provided over weekends when services are a minimum. The increased mortality over weekends for certain conditions in the National Health Service (NHS) in England has led to an intense debate on reconfiguring the health service. Little is known about the impact of the weekend effect on severe acute kidney requiring dialysis (AKI-D) in England, the incidence of which has increased more than 12-foldover the past 15 years. Most nephrology departments in England provide continuous consultant cover over weekends and have the capacity to perform emergency dialysis as needed over weekends suggesting that a weekend effect is less likely to occur. Patients admitted over the weekend may present in three ways - with severe AKI requiring dialysis over the weekend, with AKI and requiring dialysis on a subsequent weekday or with no AKI, but develop AKI-D during the in-patient stay over next few days. Some studies have reported that patients starting dialysis on Sunday or a diagnosis of severe AKI over weekend, does not affect mortality, while others have reported increased mortality for AKI in all sizes of hospital over weekend. One explanation for this observation is that necessary dialysis therapy may not be initiated on a weekend as a result of limitations in physician or nurse staffing or device availability. However, bias can be created by single center studies as it is well recognized that the epidemiology of AKI-D shows considerable regional variation and this may be true for all days of the week. It can also be speculated that patients admitted on weekends may not receive optimal care resulting in development of new AKI or progression of AKI to AKI-D resulting in excess mortality.

With this background, the investigators wanted to investigate whether a weekend effect on mortality exists for AKI-D patients in England. The investigators hypothesized that patients admitted over weekend would have increased mortality irrespective of demographic features and clinical characteristics. They also hypothesized that the effect on mortality would be more pronounced in centers with no on-site nephrology services.
The active ingredient in famotidine tablets, USP is a histamine H2-receptor antagonist. Famotidine is N’(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide. The molecular formula of famotidine is C8H15N7O2S3 and its molecular weight is 337.45. Its structural formula is:

Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol. 

Each tablet for oral administration contains either 20 mg or 40 mg of famotidine and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, Opadry OY 52945 Yellow, pregelatinized starch and talc. The composition of Opadry OY 52945 Yellow, used for film coating of famotidine tablets, is as follows: hydroxypropyl methylcellulose, polyethylene glycol 400, synthetic yellow iron oxide and titanium dioxide.
BACKGROUND: Accurate estimation of SARS-CoV-2 re-infection is crucial to understanding the connection between infection burden and adverse outcomes. However, relying solely on PCR testing results in underreporting. We present a novel approach that includes longitudinal serologic data, and compared it against testing alone among people experiencing homelessness.
METHODS: We recruited 736 individuals experiencing homelessness in Toronto, Canada, between June and September 2021. Participants completed surveys and provided saliva and blood serology samples every three months over 12 months of follow-up. Re-infections were defined as: positive PCR or rapid antigen test (RAT) results > 90 days after initial infection; new serologic evidence of infection among individuals with previous infection who sero-reverted; or increases in anti-nucleocapsid in seropositive individuals whose levels had begun to decrease.
RESULTS: Among 381 participants at risk, we detected 37 re-infections through PCR/RAT and 98 re-infections through longitudinal serology. The comprehensive method identified 37.4 re-infection events per 100 person-years, more than four-fold more than the rate detected through PCR/RAT alone (9.0 events/100 person-years). Almost all test-confirmed re-infections (85%) were also detectable by longitudinal serology.
CONCLUSIONS: Longitudinal serology significantly enhances the detection of SARS-CoV-2 re-infections. Our findings underscore the importance and value of combining data sources for effective research and public health surveillance.
For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion "squats with 90° knee angle, semi-squats with 120° knee angle" and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions.
This group will receive Pelvic PNF protocol. The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Hydroxyprogesterone caproate injection is a clear, yellow solution. The solution must be clear at the time of use; replace vial if visible particles or crystals are present. 

Hydroxyprogesterone caproate injection single-dose vials are only for intramuscular injection with a syringe into the upper outer quadrant of the gluteus maximus, rotating the injection site to the alternate side from the previous week, using the following preparation and administration procedure: 

  


  1. Clean the vial top with an alcohol swab before use.
  2. Draw up 1 mL of drug into a 3 mL syringe with an 18 gauge needle.
  3. Change the needle to a 21 gauge 1½ inch needle.
  4. After preparing the skin, inject in the upper outer quadrant of the gluteus maximus. The solution is viscous and oily. Slow injection (over one minute or longer) is recommended.
  5. Applying pressure to the injection site may minimize bruising and swelling.
Asthma and obesity are two major public health problems worldwide. It is now well established that there is a strong link between obesity and asthma. Management of obese patients with asthma is complex in clinical practice because, compared to asthma patients with a normal weight, obese patients with asthma are more prone to respiratory symptoms, asthma attacks and hospital admissions. Lower sensitivity to asthma treatments has also been observed. Indeed, obese patients with moderate to severe asthma respond less well to inhaled corticosteroids, which constitute the recommended treatment for asthma. Improved therapeutic strategies are required for obese patients with uncontrolled asthma.